Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin L Sos

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Nature Communications|November 9, 2018
Overcoming EGFR<sup>G724S</sup>-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitorsJana Fassunke, Fabienne Müller, Marina Keul, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2019
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic PathwaysMatthias Scheffler, Michaela A Ihle, Rebecca Hein, et al.
The Journal of Clinical Investigation|May 20, 2009
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesionsMartin L Sos, Kathrin Michel, Thomas Zander, et al.
JCO Precision Oncology|September 11, 2020
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung CancerSebastian Michels, Carina Heydt, Bianca van Veggel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2020
New Approaches to SCLC Therapy: From the Laboratory to the ClinicJohn T Poirier, Julie George, Taofeek K Owonikoko, et al.
Science Translational Medicine|December 17, 2010
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancerJonathan Weiss, Martin L Sos, Danila Seidel, et al.
Cancer Discovery|February 14, 2012
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancerPeter S Hammerman, Martin L Sos, Alex H Ramos, et al.
Nature|February 25, 2026
A disease model resource reveals core principles of tissue-specific cancer evolutionSebastian Mueller, Niklas de Andrade Krätzig, Markus Tschurtschenthaler, et al.
Nature|September 10, 2025
Functional synapses between neurons and small cell lung cancerVignesh Sakthivelu, Anna Schmitt, Franka Odenthal, et al.
Nature Genetics|September 4, 2012
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancerMartin Peifer, Lynnette Fernández-Cuesta, Martin L Sos, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Nature Communications|November 9, 2018
Overcoming EGFR<sup>G724S</sup>-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitorsJana Fassunke, Fabienne Müller, Marina Keul, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2019
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic PathwaysMatthias Scheffler, Michaela A Ihle, Rebecca Hein, et al.
The Journal of Clinical Investigation|May 20, 2009
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesionsMartin L Sos, Kathrin Michel, Thomas Zander, et al.
JCO Precision Oncology|September 11, 2020
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung CancerSebastian Michels, Carina Heydt, Bianca van Veggel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2020
New Approaches to SCLC Therapy: From the Laboratory to the ClinicJohn T Poirier, Julie George, Taofeek K Owonikoko, et al.
Science Translational Medicine|December 17, 2010
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancerJonathan Weiss, Martin L Sos, Danila Seidel, et al.
Cancer Discovery|February 14, 2012
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancerPeter S Hammerman, Martin L Sos, Alex H Ramos, et al.
Nature|February 25, 2026
A disease model resource reveals core principles of tissue-specific cancer evolutionSebastian Mueller, Niklas de Andrade Krätzig, Markus Tschurtschenthaler, et al.
Nature|September 10, 2025
Functional synapses between neurons and small cell lung cancerVignesh Sakthivelu, Anna Schmitt, Franka Odenthal, et al.
Nature Genetics|September 4, 2012
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancerMartin Peifer, Lynnette Fernández-Cuesta, Martin L Sos, et al.
Pageof 6